CJC 1295 No DAC with Ipamorelin is a synthetic peptide combination evaluated in laboratory research for its dual-action stimulation of the somatotropic axis. By pairing a Growth Hormone-Releasing Hormone (GHRH) analog with a selective ghrelin receptor agonist, this blend produces a synergistic, pulsatile release of endogenous growth hormone (GH) and downstream insulin-like growth factor 1 (IGF-1) in preclinical models.
CJC 1295 No DAC with Ipamorelin is a synthetic peptide combination evaluated in laboratory research for its dual-action stimulation of the somatotropic axis. By pairing a Growth Hormone-Releasing Hormone (GHRH) analog with a selective ghrelin receptor agonist, this blend produces a synergistic, pulsatile release of endogenous growth hormone (GH) and downstream insulin-like growth factor 1 (IGF-1) in preclinical models.
In laboratory research settings, the combination of cjc 1295 no dac with ipamorelin represents one of the most widely investigated dual-peptide formulations for studying growth hormone secretagogue (GHS) pathways. CJC-1295 No DAC—also frequently designated as Modified GRF 1-29—is a tetrasubstituted 29-amino acid peptide derivative of natural GHRH. The chemical modification at positions 2, 8, 15, and 27 confers increased enzymatic stability against dipeptidyl peptidase-IV (DPP-IV) cleavages while retaining full binding affinity for the anterior pituitary GHRH receptor.
Ipamorelin, conversely, is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a highly selective agonist of the Growth Hormone Secretagogue Receptor (GHSR-1a), commonly referred to as the ghrelin receptor. When co-administered in in vitro or preclinical animal models, these two distinct chemical structures target complementary signaling pathways on somatotropes. The result is a amplified transcription and release of GH that exceeds the additive effects of either peptide administered independently.
To understand the biochemical synergy of cjc 1295 no dac with ipamorelin, researchers evaluate how each sequence engages its respective membrane receptor on pituitary somatotropes. CJC-1295 No DAC binds directly to the GHRH receptor, a Class B G-protein-coupled receptor. This binding event activates the stimulatory G-protein sub-unit (Gαs), triggering adenylate cyclase to convert ATP into cyclic adenosine monophosphate (cAMP). Elevated intracellular cAMP activates Protein Kinase A (PKA), which phosphorylates voltage-gated calcium channels, prompting extracellular calcium influx and transcriptional activation of the GH gene.
Concurrently, ipamorelin engages the GHSR-1a receptor, which is coupled to the Gαq/11 protein subunit. Activation of this pathway stimulates phospholipase C (PLC), facilitating the cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 triggers the immediate release of stored intracellular calcium from the endoplasmic reticulum. The simultaneous surge in both cAMP/PKA signaling and intracellular calcium release produces a profound, coordinated exocytosis of GH-containing secretory vesicles without elevating secondary hormones like cortisol or prolactin.
A critical distinction in secretagogue research is the structural difference between CJC-1295 No DAC and CJC-1295 DAC (Drug Affinity Complex). As detailed in our CJC-1295 No DAC vs DAC research guide, the inclusion of the maleimidopropionic acid linker in the DAC variant enables covalent binding to circulating serum albumin. This modification extends the plasma half-life of CJC-1295 DAC to approximately 6 to 8 days in animal models, resulting in chronic, non-pulsatile elevation of growth hormone levels.
For research paradigms designed to model physiological hormone release, cjc 1295 no dac is preferred. Lacking the albumin-binding affinity complex, Mod GRF 1-29 exhibits a half-life of approximately 30 minutes in vivo. When paired with Ipamorelin, which possesses a similar short half-life (~2 hours in rodent assays), the combination mimics natural discrete GH pulses. This preserves normal receptor sensitivity and avoids the potential down-regulation or desensitization of somatotrope receptors associated with continuous GHRH stimulation.
Preclinical trials investigating growth hormone secretagogues consistently show that co-activation of GHRH and GHSR-1a receptors produces a sharp rise in peak plasma GH concentration within 15 to 30 minutes post-exposure. In rodent models, this transient spike triggers hepatic secretion of insulin-like growth factor 1 (IGF-1) and its primary circulating carrier, IGF-binding protein-3 (IGFBP-3).
Data compiled across numerous in vivo studies suggest that sustained regulation of the GH/IGF-1 axis via short-acting secretagogues promotes downstream anabolic signaling cascades. Specifically, elevated circulating IGF-1 activates the phosphoinositide 3-kinase (PI3K) / Akt / mammalian target of rapamycin (mTOR) pathway in target tissues. Researchers examining muscle protein synthesis, cartilage extracellular matrix maintenance, and lipid oxidation frequently utilize this combination to analyze acute versus chronic somatotropic responses.
In vitro cellular assays and preclinical animal models demonstrate that combining cjc 1295 no dac with ipamorelin markedly influences connective tissue turnover and cell proliferation metrics. IGF-1 upregulation downstream of secretagogue exposure stimulates collagen mRNA expression in tenocytes and chondrocytes, providing a mechanism for investigating musculoskeletal repair mechanisms.
Furthermore, metabolic research indicates that ghrelin receptor activation combined with GHRH signaling enhances lipolysis in adipose tissue. In murine models of metabolic dysregulation, administration of these secretagogues correlates with increased expression of hormone-sensitive lipase (HSL) and uncoupling protein-1 (UCP-1), making the dual-peptide complex a valuable model for examining body composition shifts and mitochondrial energy expenditure.
When designing comparative research studies, investigators often evaluate multiple peptides within the GHRH and GHRP classes. The table and analysis below highlight key biochemical differences between common growth hormone secretagogue compounds cataloged in our all peptides directory.
While earlier-generation peptides like sermorelin share the native 29-amino acid core of GHRH, CJC-1295 No DAC incorporates four amino acid substitutions that enhance resistance to enzymatic degradation. Similarly, while older GHRP compounds such as ghrp-2 or GHRP-6 activate the GHSR-1a receptor effectively, they frequently trigger non-selective rises in ACTH, cortisol, and prolactin. Ipamorelin remains distinct in literature due to its extreme selectivity for GHSR-1a, leaving secondary pituitary hormones unaltered even at high experimental concentrations.
To preserve structural integrity and prevent peptide bond hydrolytic cleavage, lyophilized vials of cjc 1295 no dac with ipamorelin must be handled in accordance with strict laboratory standard operating procedures. Lyophilized powders should be stored upon receipt at -20°C or -80°C for long-term stability.
Reconstitution should be performed using sterile bacteriostatic water (0.9% benzyl alcohol) or laboratory-grade sterile saline depending on downstream assay requirements. Diluent should be introduced gently along the glass wall of the vial to avoid shear stress on the peptide chains. Once reconstituted, the liquid solution should be aliquoted to avoid repeated freeze-thaw cycles and maintained at 2°C to 8°C. For detailed protocols on maintaining peptide integrity in experimental setups, visit our dedicated PX1 research library.
Research outcomes depend entirely on compound purity, chemical identity, and the absence of contaminants. At PX1 Research, every batch of cjc 1295 no dac with ipamorelin undergoes rigorous quality verification in ISO 17025 accredited third-party laboratories within the United States.
Analytical verification includes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity standards exceeding 98.0%, combined with Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm exact molecular weight and amino acid sequencing. Additionally, every lot is subjected to Limulus Amebocyte Lysate (LAL) testing to ensure bacterial endotoxin levels remain strictly below <0.5 EU/mg. Every product shipment includes lot-traceable Certificates of Analysis (COAs) accessible directly by research facilities.
Reliable academic and industrial research requires consistent batch-to-batch reproducibility and fast distribution turnaround. PX1 Research operates compliant US-based manufacturing and storage facilities, dispatching orders same-day from centralized hubs in California and Arizona.
Principal investigators and laboratory managers seeking bulk quantities or custom formulation ratios for high-throughput screening assays can utilize our institutional portal at PX1 wholesale procurement. All compounds are strictly synthesized, packaged, and distributed for in vitro and preclinical research applications only.
What is CJC-1295 No DAC with Ipamorelin?
It is a research blend combining a modified Growth Hormone-Releasing Hormone analog (Mod GRF 1-29) and a selective ghrelin receptor agonist (Ipamorelin) to study synergistic growth hormone secretagogue pathways in laboratory settings.
How does CJC-1295 No DAC differ from CJC-1295 DAC?
CJC-1295 No DAC lacks the Drug Affinity Complex (maleimidopropionic acid linker), resulting in a short half-life (~30 minutes) that yields pulsatile GH release. CJC-1295 DAC binds to serum albumin, extending its half-life to several days and causing continuous elevation of GH levels.
Why are GHRH analogs and GHRPs studied together?
Preclinical studies show that targeting both the GHRH receptor (via CJC-1295 No DAC) and the GHSR-1a receptor (via Ipamorelin) produces a synergistic release of growth hormone greater than the sum of either peptide administered alone.
What purity levels does PX1 Research guarantee for this compound?
PX1 Research provides peptides with a minimum of 98.0% purity verified by RP-HPLC and mass spectrometry, accompanied by lot-specific COAs confirming endotoxin levels below <0.5 EU/mg.
What reconstitution solvent should be used for laboratory assays?
Lyophilized vials are typically reconstituted using sterile bacteriostatic water (containing 0.9% benzyl alcohol) to maintain solution sterility for multi-use laboratory testing.
How should reconstituted CJC-1295 No DAC / Ipamorelin be stored?
Reconstituted liquid solutions should be stored under refrigeration at 2°C to 8°C and used within 30 days. Unreconstituted lyophilized powder should be stored at -20°C or -80°C for long-term preservation.
Does Ipamorelin elevate cortisol or prolactin levels in preclinical models?
Unlike earlier GHRPs such as GHRP-2 or GHRP-6, preclinical literature demonstrates that Ipamorelin is highly selective for GHSR-1a and does not significantly stimulate cortisol, ACTH, or prolactin secretion.
Are PX1 Research compounds available for human administration?
No. All products sold by PX1 Research are strictly intended for in vitro, preclinical, and laboratory research use only. They are not for medical, diagnostic, therapeutic, or human consumption.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.